Dossier assessment
Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with relapsed or refractory multiple myeloma
Result of dossier assessment:
- Patients who have received 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy: added benefit not proven
- Patients who have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy: added benefit not proven
Press releases
A further treatment option for multiple myeloma in late-line treatment: more an unmet evidence need than an unmet medical need
Linvoseltamab is another bispecific antibody now available, but the results of a comparative study are not expected until 2026.
Project details
- Project no.
- A25-127
- Commission
- Commission awarded on 01.10.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-127_en